new_0222_0431|ABOS|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_0222_0431|ABOS|Long Name|1|1|Acumen Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|Acumen Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|Acumen Pharmaceuticals Inc Inventories (Quarterly) (USD)|Acumen Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|Acumen Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|Acumen Pharmaceuticals Inc Book Value (Quarterly) (USD)|Acumen Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|Acumen Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|Acumen Pharmaceuticals Inc EV to Revenues|Acumen Pharmaceuticals Inc EV to Earnings|Acumen Pharmaceuticals Inc EV to Free Cash Flow|Acumen Pharmaceuticals Inc EV to Assets (Quarterly)|Acumen Pharmaceuticals Inc PS Ratio|Acumen Pharmaceuticals Inc PE Ratio|Acumen Pharmaceuticals Inc Price to Book Value|Acumen Pharmaceuticals Inc PEG Ratio|Acumen Pharmaceuticals Inc Debt to Equity Ratio|Acumen Pharmaceuticals Inc Dividend Yield|Acumen Pharmaceuticals Inc Shareholder Yield (TTM)|Acumen Pharmaceuticals Inc Percent of Shares Outstanding Short|Acumen Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Payables (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|Acumen Pharmaceuticals Inc Return on Invested Capital|Acumen Pharmaceuticals Inc Quality Ratio Score|Acumen Pharmaceuticals Inc Momentum Score|Acumen Pharmaceuticals Inc Beta (1Y)|Acumen Pharmaceuticals Inc Sustainable Growth Rate (TTM)|Acumen Pharmaceuticals Inc Institutional Investor Ownership Percentage|Acumen Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|Acumen Pharmaceuticals Inc Total Employees (Annual)|Acumen Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|Acumen Pharmaceuticals Inc Shares Outstanding|Acumen Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|Acumen Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|Acumen Pharmaceuticals Inc Payout Ratio|Acumen Pharmaceuticals Inc Quick Ratio (Quarterly)|Acumen Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|Acumen Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|Acumen Pharmaceuticals Inc Effective Tax Rate (TTM)|Acumen Pharmaceuticals Inc Return on Equity|Acumen Pharmaceuticals Inc Net Income (TTM) (USD)|Acumen Pharmaceuticals Inc Revenue (TTM) (USD)|Acumen Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|Acumen Pharmaceuticals Inc Revenue (Quarterly) (USD)|Acumen Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|Acumen Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|Acumen Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|Acumen Pharmaceuticals Inc Net Income (Quarterly) (USD)|Acumen Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|Acumen Pharmaceuticals Inc Price (USD)|Acumen Pharmaceuticals Inc Total Return Price (USD)|Acumen Pharmaceuticals Inc Enterprise Value (USD)|Acumen Pharmaceuticals Inc 30-Day Average Daily Volume|Acumen Pharmaceuticals Inc 1 Year Price Returns (Daily)
new_0222_0431|ABOS|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_0222_0431|ABOS||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly
new_0222_0431|ABOS||5|5|91|91|0|92|0|91|91|91|0|91|91|0|1.44230769231|0|1.44230769231|0|1.44230769231|0|1.44086021505|0|0|1.44230769231|0|15.3846153846|91|91|91|0|0|0|0|0|30.6666666667|91.3333333333|0|91.3333333333|28.8|0|91|0|0|91.3333333333|91.25|0|0|91|0|0|91.6666666667|0|91.3333333333|91.3333333333|91.3333333333|91.3333333333|1.44230769231|1.44230769231|1.44230769231|1.44094488189|0
new_0222_0431|ABOS||6|6|3|3|0|1|0|3|3|3|0|3|3|0|156|0|156|0|156|0|93|0|0|156|0|13|3|3|3|0|0|0|0|0|6|6|0|6|5|0|3|0|0|6|4|0|0|3|0|0|3|0|6|6|6|6|156|156|156|127|0
new_0222_0431|ABOS||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_0222_0431|ABOS|202003|202003|202003||||||||||||||||||||||||||||||||||28.6518||-0.0714||||||-0.0714|||||||0.226||0.222|-2.045|-2.045|0.001|||||
new_0222_0431|ABOS|202006|202006|202006||||||||||||||||||||||||||||||||||28.6518||-0.071||||||-0.071|||||||0.151||0.259|-2.035|-2.035|0|||||
new_0222_0431|ABOS|202009|202009|202009||||||||||||||||||||||||||||||||||28.6518||-0.0869||||||-0.0869|0||||||0.73||0.226|-2.49|-2.49|0|||||
new_0222_0431|ABOS|202012|202012|202012|44.429|43.777||||63.02|6.367|56.653||-18.591|-26.965||||||||||0||||0.109|0.531|0|||||||28.6518||-0.0468|||38.6518|0|6.8927|-0.0264||||-7.325|1.436||0.329||0.644|-0.755|-0.755|0|||||
new_0222_0431|ABOS|202103|202103|202103|42.103|41.407||||87.835|31.182|56.653||-45.462|-53.962||||||||||||||0.109|0.918|0|||||||28.6518|7|-0.13|||38.6518|||0.6803||||-32.277|||||1.215|-26.997|-26.997|0.004|||||
new_0222_0431|ABOS|202106|202106|202106|70.572|68.812||0.006||179.022|4.518|174.504||-106.079|-115.32||||||||||||||0.109|2.907|0|||||||38.6518||-1.659|36.9851||38.6518|||-0.16||||-91.6|||||1.187|-61.358|-61.358|0.004|||||
new_0222_0431|ABOS|202107|202106|202106|||||||||||||384.9149||-51.3029||335.8146|||||0||0.0791|||||||||29.1861||||40.1518||||||||||||||||||15.48|15.48|552.7379||
new_0222_0431|ABOS|202108|202106|202106|||||||||||||457.0866||-60.9223||388.7466|||||0||0.0249|||||||||29.0642||||40.4681||||||||||||||||||17.92|17.92|656.3764|160434.4|
new_0222_0431|ABOS|202109|202109|202109|204.913|199.964||0.013||1.489|1.489|0||233.36|-119.222||279.5436|-54.802|-23.3672|9.0352|347.2386||2.5771|||0||1.6751|0.109|0.382|0.004||||||77.1902|38.2666||-0.1|40.4703||40.4703|||-0.1|-168.559|||-93.012|||||2.135|-3.902|-3.902|0.014|14.86|14.86|401.4247|263622.0667|
new_0222_0431|ABOS|202110|202109|202109|||||||||||||256.7157||-21.459||328.3111||2.4366|||0||1.6499|||||||||77.3547||||||||||||||||||||||14.05|14.05|368.6437|107486.8|
new_0222_0431|ABOS|202111|202109|202109|||||||||||||83.3923||-6.9708||184.602||1.3701|||0||1.4676|||||||||76.9711||||40.4703||||||||||||||||||7.9|7.9|119.7514|54367.6333|
new_0222_0431|ABOS|202112|202112|202112|||||||||||||51.2641||-4.2852||157.9632||1.1723|||0||2.487|||||||||75.082||||||||||||||||||||||6.76|6.76|73.6152|147303.1667|
new_0222_0431|ABOS|202201|202112|202112|||||||||||||5.0445||-0.4217||119.6408||0.8879|||0||2.4845|||||||||75.074||||||||||||||||||||||5.12|5.12|7.2439|229944.7333|
new_0222_0431|ABOS|202202|202112|202112|||||||||||||12.6538||-1.0577||125.9499||0.9348|||0|||||||||||||||||||||||||||||||||5.39|5.39|18.1709|269855.9333|